+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 79 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
M

Actively Recruiting

Researchers are evaluating the efficacy and safety of duvakitug in people with moderately to severely active Crohns Disease through a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study. The study includes a 40-week pivotal maintenance sub-study followed by a 240-week open-label extension sub-study, with a total duration of up to 286 weeks. Participants must have previously responded to treatment and completed endoscopy in a prior study phase. Participants receive subcutaneous injections of duvakitug or placebo according to the study protocol during the maintenance period. Those who complete the maintenance sub-study may continue in the open-label extension sub-study for longer-term treatment and monitoring. The treatment duration can be up to 280 weeks, including both study periods, with a total of up to 43 on-site visits planned. Throughout the trial, participants attend regular visits for assessments including clinical remission measured by the Crohns Disease Activity Index CDAI, endoscopic response, and patient-reported outcomes. Safety is monitored by tracking adverse events and antidrug antibody development. After treatment, participants have a 45-day follow-up visit. The study evaluates outcomes at Week 40 and continues monitoring throughout the extension period.

Age: 16Years - 80YearsAll GendersPhase 3
109 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of duvakitug in people with moderately to severely active Ulcerative Colitis UC. This Phase 3, multicenter, randomized, double-blind, placebo-controlled maintenance study aims to understand how well duvakitug works to maintain clinical remission and improve symptoms in participants with UC. The trial is sponsored by Sanofi and includes a large, diverse participant group aged 16 to 80 years. Participants receive subcutaneous injections of either one of three doses of duvakitug or a placebo following the study protocol. The study consists of two main periods a 40-week Pivotal Maintenance Sub-Study and a 240-week Open-Label Extension OLE Sub-Study. Those who do not join the OLE will complete a 45-day follow-up after the maintenance phase. Across both periods, participants may have up to 32 on-site visits to monitor treatment and health status. During the study, participants will undergo various assessments including endoscopy, clinical response evaluations, and symptom scoring by modified Mayo Score. Researchers will monitor clinical remission, endoscopic and histologic improvements, corticosteroid use, fatigue, abdominal pain, quality of life, and hospitalization incidence. Safety will be closely tracked through adverse event reporting and measurement of drug concentration and immune response. The total participation duration can be up to 286 weeks, allowing long-term monitoring of duvakitugs effects.

Age: 16Years - 80YearsAll GendersPhase 3
171 locations
M

Actively Recruiting

Researchers are collecting and creating a labeled ultrasound image data set from patients undergoing routine ultrasound scans of their lower limbs due to suspected deep vein thrombosis DVT. This observational study aims to gather imaging data, patient information, and ultrasound metadata to train artificial intelligence AI models that can automatically detect DVT from conventional ultrasound scans. The study is part of the ThrombUS project, which focuses on developing tools for early and automated DVT diagnosis to improve patient safety and outcomes. The study involves selecting patients suspected of having DVT who are referred for ultrasound scans. These patients, both inpatients and outpatients, will be consecutively included to ensure diversity of demographics, medical conditions, and ultrasound operators. The collected data will include ultrasound image series and video clips, along with anonymized patient demographics, referral notes, medical conditions, scan diagnoses, operator IDs, and ultrasound equipment details. The anonymized data set will be prepared according to regulations for research use and shared publicly through European science portals. Participants will undergo routine ultrasound scans for suspected DVT, and their scan data and related information will be collected and anonymized. The primary outcome is the ultrasound data collected on the day of the scan. The data set will support AI model training and research, with the anonymized information made available for further study. Participation involves providing informed consent and allowing the inclusion of their scan data and metadata. The study will monitor data quality and maintain privacy throughout, with no interventional treatments involved.

Age: 18Years +All Genders
5 locations
P

Actively Recruiting

Researchers are evaluating calderasib alone and in combination with other therapies for people with advanced solid tumors that have a specific KRAS G12C mutation. The study is designed to assess the safety, how the body processes the drug pharmacokinetics, and the effectiveness of calderasib and its combinations. Participants have advanced cancers confirmed by specific tests and have often received prior treatments. Participants are assigned to one of several groups receiving different treatments. Some receive daily oral doses of calderasib alone with doses increasing up to 800 mg, adjusted as needed for safety. Others receive calderasib combined with pembrolizumab infusions every 21 days for up to 35 cycles 24 months, sometimes with additional chemotherapy drugs like carboplatin, pemetrexed, cetuximab, oxaliplatin, leucovorin, or 5-fluorouracil according to standard dosing schedules. Treatments continue until the disease progresses or participants stop. During the study, participants have regular visits for drug dosing and safety monitoring. Researchers track side effects, dose-limiting toxicities, and treatment discontinuations over months. Blood samples are taken at specific times to measure drug levels and how the body absorbs and clears calderasib. The main outcomes include safety measures up to about 56 months and response rates. This long study period helps understand how participants respond and tolerate the treatments over time.

Age: 18Years +All GendersPhase 1
75 locations
E

Actively Recruiting

Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.

Age: 18Years +All GendersPhase 3
182 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
E

Actively Recruiting

Researchers are evaluating orelabrutinib, a brain-penetrating BTK inhibitor, in patients with non-active Secondary Progressive Multiple Sclerosis SPMS. This phase 3, randomized, double-blind, multicenter study compares the effects and safety of orelabrutinib against placebo. About 990 participants will be enrolled globally and randomly assigned in a 21 ratio to receive either orelabrutinib or placebo. The study aims to assess disability progression and other neurological outcomes in this population. Participants will undergo a screening period of up to 4 weeks before starting treatment. The treatment period varies individually, lasting approximately 24 to 60 months, with a minimum of 12 months of double-blind treatment where participants receive either daily orelabrutinib orally or placebo. Participants showing confirmed disability progression at 24 weeks may continue in a 2-year open-label phase receiving orelabrutinib. After treatment ends, a 4-week safety follow-up is conducted unless participants join a long-term safety study where treatment continues. During the study, participants will be monitored regularly to track disability progression confirmed over 24 weeks and other outcomes including MRI lesions, relapse rates, and functional test results. Safety and tolerability of orelabrutinib are also assessed throughout up to about 120 weeks. All active participants will have a final study visit near the study end date, with additional safety follow-up visits when applicable. The total study duration can extend up to several years depending on individual participation and treatment phase.

Age: 18Years - 60YearsAll GendersPhase 3
90 locations
O

Actively Recruiting

Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.

Age: 50Years +All GendersPhase 3
566 locations
V

Actively Recruiting

Researchers are studying vedolizumab, a medicine designed to reduce inflammation and pain in the digestive system, for children and teenagers with moderate to severe Crohns disease who have not responded well or were intolerant to standard treatments. The main goal is to see if participants can achieve remission, meaning their symptoms improve or disappear and endoscopy shows no inflammation. This phase 3, randomized, double-blind study involves about 120 pediatric participants worldwide. Participants will receive three intravenous infusions of vedolizumab over six weeks during the Induction Period, with doses based on their weight. Those who show a clinical response at Week 14 will be randomly assigned to receive either a high or low dose of vedolizumab every eight weeks up to Week 46 during the Maintenance Period. Dose adjustments may be made if disease worsens, and corticosteroid rescue therapy is allowed once during maintenance. After Week 54, eligible participants may continue treatment in an extension study or enter long-term follow-up. Throughout the study, participants will undergo assessments including clinical evaluations, endoscopies, and laboratory tests to measure disease activity and remission using tools like the Pediatric Crohns Disease Activity Index and Simple Endoscopic Score for Crohns Disease. Safety will be monitored through reports of adverse events and antibody levels against vedolizumab. The total participation can include additional safety visits and up to two years of long-term follow-up after the last dose.

Age: 2Years - 17YearsAll GendersPhase 3
96 locations

1-10 of 79

1